Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Product·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Amgen has announced positive topline results from its Phase 3 study of dazodalibep for moderate-to-severe systemic Sjögren's disease. The drug, acquired through Amgen's buyout of Horizon Therapeutics, has shown success in this clinical trial.
The results mark a significant milestone for Amgen as it continues to develop therapies for autoimmune diseases. Dazodalibep's performance in the trial could enhance Amgen's portfolio in the biopharmaceutical market.
Amgen
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE”
SEC Filing — AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE“<figure><div><img”
biopharma dive — Amgen reports a Phase 3 win with Sjögren’s drug candidate